1. **References:**

1. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg. 2003;69(6):624–8
2. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22(12):552–7
3. Ansari MY, Dikhit MR, Sahoo GC, Das P (April 2012). "Comparative modeling of HGPRT enzyme of L. donovani and binding affinities of different analogs of GMP". Int. J. Biol. Macromol.50 (3): 637–49
4. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa C, Coffman R, Johnson W, Carvalho E (1996). "Interleukin-12 Restores Interferon-gamma Production and Cytotoxic Responses in Visceral Leishmaniasis". J Infect Dis 173 (6): 1515–1518
5. Banjara MR, Hirve S, Siddiqui NA, Kumar N, Kansal S, Huda MM, et al. Visceral Leishmaniasis Clinical Management in Endemic Districts of India, Nepal, and Bangladesh. Journal of Tropical Medicine. 2012;1-8
6. Bern C Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD ET AL. Factor associated with VL in Nepal; Bed net use is strongly protective. Am J Trop Med Hyg 2000; 63 (3,4) 184 – 8
7. Bern C, Hightowere AW, Chowdhary R, Ali M, Amann J, Wagatsuma Y, Haque R, Kurkjian K, Vaz LE, Begum M, Akter T, Cetre-Sossah CB, Ahluwalia IB, Dotson E, Secor WE, Breiman RF, Maguire JH. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005 May;11(5):655-62
8. Bhattacharya SK Sur D, Karbwang J. Childhood Visceral Leishmaniasis. Indian J Med Res 2006; 123: 353 – 356
9. Bista MB, National over view of kala azar in NepalBastola S, Karki P, Rijal s, Gautam A, editors. Kala azar in Nepal: Principles practice and public health perspectives EDCD/WHO/BPKIHS, Nepal, 1998
10. Boelaert M, Meheus F, Robays J, Lutumba P. Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol. 2010 Oct;104(7):535-42
11. Boelaert M, Meheus F, Snachez A, Singh SP, Venlerberghe V, Picado A, Meeseen B, Sundar S. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009 Jun;14(6):639-44
12. Bora D. Epidemiology of visceral leishmaniasis in India. NMJI. 1999;12(2)

13. Carvalho E, Badaro R, Reed S, Jones T, Johnson W (1985). Absence of Gamma Interferon and Interleukin 2 Production During Active Visceral Leishmaniasis. J Clin Invest 76 (6): 2066–2069
14. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M (2006). A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral Leishmaniasis. Brit Med J 333 (7571): 723–6
15. Cross ER, Hyams KC. The potential effect of global warming on the geographic and seasonal distribution of Phlebotomus papatasi in Southwest Asia. Environment Health Perspectives 1996; 104 (7): 724 – 727
16. Custodio E, Gasdisa E, Sordo L, Cruz I, Mereno J, Nieto J, Chicharro C, Aseffa A, Abraham Z, Hailu T, Canavate C. Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia. PLoS Negl Trop. Dis. 2012;6(9):e1813. Epub 2012 Sep 27
17. Das ML, Kumar V, Roy L, Kumar R, Boelaert M, Davies CR et al. House hold rish factors for Phlebotomus argentipes, Leishmania vector, density in India and Nepal 2009 (3 – 7 February); Oral presentation in World Leish 4, Lucknow, India
18. Bern C Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD ET AL. Factor associated with VL in Nepal; Bed net use is strongly protective. Am J Trop Med Hyg 2000; 63 (3,4) 184 – 8
19. Desjeux P. (2001). "The increase of risk factors for leishmaniasis worldwide". Transactions of the Royal Society of Tropical Medicine and Hygiene 95 (3): 239–43
20. Devkota UN Descriptive Epidemiology of VL in Nepal. J Nep Med Assoc 1993; 31: 329 – 336
21. Ganguly S, Mukhopadhyay D, Das NK, et al. (April 2010). "Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis". J. Invest. Dermatol. 130 (4): 1013–22
22. Ghalib H, Piuvezam M, Skeiky Y (1993). Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92 (1): 324–329
23. Ghalib H, Whittle J, Kubin M, Hashim F, El-Hassan A, Grabstein K, Trinchieri G, Reed S (1995). "IL-12 Enhances Th1-Type Responses in Human Leishmania donovani Infections". J Immunol 154 (9): 4623–4629
24. Hamal P., Shrestha HG, Dali S, Kala azar diagnosis in bone marrow and pattern of clinical presentation in TU teaching hospital. J Nep Med Assoc 1993: 31 8 – 15
25. HarperCollins Publishers, 1991, 1994, 1998, 2000, 2003.". Kala azar. Retrieved 2013-06-21

26. Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S Visceral leishmaniasis in rural bihar, India, Emerg Infect Dis. 2012 Oct;18(10):1662-4
27. Holaday BJ (1999). "Immunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasis". Mem. Inst. Oswaldo Cruz 94 (1): 55–66
28. Holaday BJ (2000). "Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis". Mem. Inst. Oswaldo Cruz 95 (2): 217–20
29. Holaday BJ, Pompeu MM, Evans T, et al. (February 1993). "Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi". J. Infect. Dis. 167 (2): 411–7
30. Holaday BJ, Pompeu MM, Jeronimo S, et al. (December 1993). Potential role for interleukin-10 in the immunosuppression associated with kala azar. J. Clin. Invest. 92 (6): 2626–32
31. Jai PN, Dash AP, Parnell B, Bhattacharya SK, Barua S, Bhatia R, et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. Bull World Health Organ. 2010;88:206–210
32. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0
33. Jean, Francois (1995). "Sudan: Speak no Evil, Do no Good". Life, Death and Aid: the Médecins Sans Frontières Report on World Crisis Intervention
34. Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, et al. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis. 2008;45:105-11
35. Joshi DD, Shamra M, Bhandari S. Visceral leishmaniasis in Nepal during 1980-2006. J Commun Dis 2006 Mar;38(2):139-48
36. Karp C, El-Safi S, Wynn T, Satti M, Kordofani A, Hashim F, Hag-Ali M, Neva F, Nutman T et al.(1993). In Vivo Cytokine Profiles in Patients with Kala-azar: Marked Elevation of Both Interleukin-10 and Interferon-gamma. J Clin Invest 91 (4): 1644–1648
37. Kemp M, Kurtzhals J, Bendtzen K, Poulsen L, Hansen M, Koech D, Kharazmi A, Theander T (1993). Leishmania donovani-Reactive Thl- and Th2-Like T-Cell Clones from Individuals Who Have Recovered from Visceral Leishmaniasis, Infect Immun 61 (3): 1069–1073

38. Koirala S, Parija SC, Karki P, Das ML. Astudy of knowledge, attitude and practices about Kala azar and its sand fly vector in rural communities of Nepal. WHO Bulletin 1998; 76 (5) 485 – 90
39. Lockwood DN, Sundar S (October 2006). "Serological tests for visceral Leishmaniasis. BMJ 333 (7571): 711–2
40. Napier LE An epidemiological consideration of the transmission of kala azar in India. Indian Med Res memoirs 1926 4: 219 – 165
41. Oliveira K, Lima FA. Forty years of visceral leishmaniasis in the state of Piaui: a review. Rev. Inst. Med. Trop. Sao Paulo. 2011;53 (1):3-11
42. Olliaro, P., Darley, S., Laxminarayan, R., et al. (2009). "Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India". Trop Med Int Health 14(8): 918–925
43. Pasquau F, Ena J, Sanchez R, et al. (June 2005). "Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region". Eur. J. Clin. Microbiol. Infect. Dis. 24 (6): 411–8
44. Perry D, Dixon K, Garlapati R, Gendernalik A, Poche D, Poche R. Visceral Leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011. Am J Trop Med Hyg 2013 Apr;88 (4):778-84. doi: 10.4269/ajtmh.12-0442. Epub 2013 Feb 4
45. Picado A, Dash AP, Bhattacharya S, Boelaert M. Vector control interventions for visceral leishmaniasis elimination initiative in South Asia, 2005-2010. Indian J Med Res. 2012 Jul;136(1):22-31
46. Ponte CB, Souza NC, Cavalcante MN, Barral AM, Aquino DM, Caldas Ade J. Risk factors for Leishmania chagasi infection in an endemic area in Raposa, State of Maranhão, Brazil.. Rev. Soc. Bras. Med. Trop. vol.44 no.6 Uberaba Nov./Dec. 2011 Epub Nov 21, 2011
47. Rajan A, Dur D, Singh VP, Siddique NA, Manna B, Lal CS, Sinha PK, Kishore K, Bhattacharya SK. Risk factors for Indian kala-azar. Am J Trop Med Hyg 2005 Jul;73(1):74-8
48. Rijal S, Koirala S, Vander SP, Boeleart M. The economic burden of visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg. 2006;100 (9):838–41
49. Saha S, Ramachandran R, Hutin YJ, Gupte MD. Visceral leishmaniasis is preventable in a highly endemic village in West Bengal, India. Trans R Soc Trop Med Hyg. 2009 Jul;103(7):737-42

50. Schenkel K, Rijal S, Koirala S, Vanlerberghe V, Van der Stuyft P, Gramiccia M, Boelaert M. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health 2006 Dec;11(12):1792-9
51. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala azar): Challenges ahead. Indian J Med Res. 2006;123:331-344
52. Singh SP, Hasker E, Picado A, Gidwani K, Malaviya P, Singh RP, Boelaert M, Sundar S Trop Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. Med Int Health 2010 Jun 15 Suppl 2:29-35
53. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, et al. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh. Comparing Yield, Feasibility and Costs. PLoS Negl Trop Dis. 2011;5 (2):960
54. Singh SP, Picado A, Boelaert M, Gidwani K, Andersen EW, Ostyn B, Meheus F, Rai M, Chappuis F, Davies C, Sundar S. The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health 2010 Jul;15 Suppl 2:12-20
55. Singh SP, Reddy DCS, Rai M, Sundar S. Serious underreporting of VL through passive case reporting in Bihar, India. Trop Med Int Health. 2006;11:899–905
56. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, et al. Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg. 2010;82:9–11
57. Sundar S, Maurya R, Singh RK, et al. (January 2006). "Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J. Clin. Microbiol. 44 (1): 251–3
58. Sundar S, Mehta H, Chhabra A, et al. (March 2006). "Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis". Clin. Infect. Dis. 42 (5): 608–13
59. Sundar S, More DK, Singh MK, et al. (October 2000). Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31 (4): 1104–7
60. Sundar S, Singh RK, Maurya R, et al. (June 2006). Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans. R. Soc. Trop. Med. Hyg.100 (6): 533–7

61. Sundar, S., Chakravarty, J., Agarwal, D., et al. (2010). "Single-dose liposomal amphotericin B for visceral leishmaniasis in India". N Engl J Med 362 (6): 504–512
62. Thakur CP. A new strategy for elimination of kala azar from rural Bihar. Indian J Med Res. 2007;126: 447-451
63. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P (1996). "Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study". Trans. R. Soc. Trop. Med. Hyg. 90 (3): 319–22
64. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A (1999). "Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases". Trans. R. Soc. Trop. Med. Hyg. 93 (3): 319–23
65. Thakur CP. A new strategy for elimination of kala azar from rural Bihar. Indian J Med Res. 2007;126: 447-451
66. Uranw S, Hasker E, Roy L, Meheus F, Dsa ML, Rijal S, Boelaert M. An outbreak investigation of visceral leishmaniasis among residents of Dharan town, eastern Nepal, evidence for urban transmission of Leishmania donovani.. BMC Infect Dis 2013 Jan 18;13:21
67. Wasan, K. M., Wasan, E. K., Gershkovich, P., et al. (2009). "Highly effective oral amphotericin B formulation against murine visceral leishmaniasis". J Infect Dis 200 (3): 557–360.